Device Trial Radar · NCT03096236
Endoscopic Full-thickness Resection of Gastric Subepithelial Tumors With the gFTRD
Last checked: Nov 19, 2026Latest source record: Sep 18, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 1, 2017
Primary completion
Mar 1, 2019
Study completion Sep 1, 2019
Sponsor
- Lead sponsor
- Kliniken Ludwigsburg-Bietigheim gGmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 30, 2017
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subepithelial gastric tumors are rare and usually detected incidentally. Most subepithelial tumors (SET) are benign but up to 13% of all lesions can be malignant. Histology after needle biopsy often brings no clear diagnosis in SET, so further strategy often remains unclear. Surveillance endoscopy can be associated with the risk of progression. Endoscopic resection usually is difficult, associated with high risk of complications and sometimes is not feasible. Surgical resection is also associated with a risk of complications and often refused by the patients. With the developement of the gFTRD-System gastric SET can now be resected endoscopically. The advantage of this technique is the complete resection and a full-thickness resections specimen for are definite histology.
Conditions
- Feasibility, Complications
Interventions
EFTRDevice
EFTR with the FTRD developed for gastric resection (gFTRD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Technical successTime frame: 1 minute (immediate)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinikum Ludwigsburg
Ludwigsburg, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.